[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 9 of about 9
1. Baroody FM, Naclerio RM: Antiallergic effects of H1-receptor antagonists. Allergy; 2000;55 Suppl 64:17-27
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The primary mechanism of antihistamine action in the treatment of allergic diseases is believed to be competitive antagonism of histamine binding to cellular receptors (specifically, the H1-receptors), which are present on nerve endings, smooth muscles, and glandular cells.
  • This notion is supported by the fact that structurally unrelated drugs antagonize the H1-receptor and provide clinical benefit.
  • On the basis of in vitro and animal experiments, drugs classified as H1-receptor antagonists have long been recognized to have additional pharmacological properties.
  • These additional properties are not uniformly distributed among drugs classified as H1-receptor antagonists.
  • It also inhibits anaphylactic release of histamine from rodent mast cells, LTC4 and LTB4 release from mouse bone-marrow-derived mast cells, LTC4 release from rat intestinal mast cells, and 5-lipoxygenase activity of polymorphonuclear neutrophils of guinea-pig intestines and rat basophilic leukaemia cells.
  • It is equally clear that these antiallergic effects are not uniformly shared among all drugs of this class.
  • [MeSH-major] Anti-Allergic Agents / immunology. Histamine H1 Antagonists / immunology. Histamine H1 Antagonists / therapeutic use. Hypersensitivity / drug therapy. Hypersensitivity / immunology
  • [MeSH-minor] Animals. Benzimidazoles / immunology. Benzimidazoles / therapeutic use. Disease Models, Animal. Humans. Receptors, Histamine H1 / immunology. Rhinitis / drug therapy. Rhinitis / immunology

  • MedlinePlus Health Information. consumer health - Allergy.
  • SciCrunch. DrugBank: Data: Chemical .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11291777.001).
  • [ISSN] 0105-4538
  • [Journal-full-title] Allergy
  • [ISO-abbreviation] Allergy
  • [Language] eng
  • [Grant] United States / NIAID NIH HHS / AI / AI45583; United States / NIDCD NIH HHS / DC / DC 02714
  • [Publication-type] Comparative Study; Journal Article; Research Support, U.S. Gov't, P.H.S.; Review
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Anti-Allergic Agents; 0 / Benzimidazoles; 0 / Histamine H1 Antagonists; 0 / Receptors, Histamine H1; 244O1F90NA / mizolastine
  • [Number-of-references] 34
  •  go-up   go-down


2. Tries S, Neupert W, Laufer S: The mechanism of action of the new antiinflammatory compound ML3000: inhibition of 5-LOX and COX-1/2. Inflamm Res; 2002 Mar;51(3):135-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: We examined the effects of ML3000 and several non-steroidal antiinflammatory drugs (NSAIDs) on the synthesis of products of 5-LOX (LTB4, LTC4) and COX-1/2 (TXB2, PGE2) in vitro and ex vivo in order to further elucidate the mechanism of action of ML3000.
  • 5-lipoxygenase inhibition was further tested in a basophilic leukemia cell assay using RBL-1 cells.
  • In carrageenan induced rat paw edema, ML3000 and indomethacin completely blocked the formation of PGE2 in the inflamed tissue.
  • MK-886 and ML3000 at 10 mg/kg p.o. reduced LTB4 production to 29.8 +/- 4.9 and 30.1 +/- 2.8 pg/mg tissue as compared to control (54.2 +/- 7.4 mg/kg tissue).
  • LTB4 levels in the rat stomach were comparable to control (2.5 +/- 0.4 pg/mg protein) after oral administration of ML3000 (10, 30, 100 mg/kg), whereas oral treatment with indomethacin (0.3, 1, 3 mg/kg) or diclofenac (1, 3 mg/kg) increased LTB4 up to 9.2 +/- 2.3 or 8.9 +/- 1.6 pg/mg protein.
  • [MeSH-minor] Adult. Animals. Colon / drug effects. Colon / metabolism. Edema / drug therapy. Edema / metabolism. Humans. Leukotriene B4 / biosynthesis. Leukotriene C4 / biosynthesis. Male. Rats. Rats, Sprague-Dawley. Rats, Wistar. Stomach / drug effects. Stomach / metabolism. Thromboxane B2 / biosynthesis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12005204.001).
  • [ISSN] 1023-3830
  • [Journal-full-title] Inflammation research : official journal of the European Histamine Research Society ... [et al.]
  • [ISO-abbreviation] Inflamm. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Acetates; 0 / Anti-Inflammatory Agents, Non-Steroidal; 0 / Cyclooxygenase Inhibitors; 0 / Lipoxygenase Inhibitors; 0 / Pyrroles; 156897-06-2 / licofelone; 1HGW4DR56D / Leukotriene B4; 2CU6TT9V48 / Leukotriene C4; 54397-85-2 / Thromboxane B2
  •  go-up   go-down


3. Knipping K, van Esch EC, Wijering SC, van der Heide S, Dubois AE, Garssen J: In vitro and in vivo anti-allergic effects of Arctium lappa L. Exp Biol Med (Maywood); 2008 Nov;233(11):1469-77
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The discovery of drugs that can be used for the treatment of allergic disease is important in human health.
  • AL was selected out of 10,000 herbal extracts in a set-up for high throughput screening in which the degree of degranulation was monitored by the release of beta-hexosaminidase from rat basophil leukemia (RBL-2H3) cells.
  • In addition, this active component was able to inhibit acute skin response in mice in vivo, indicating that AL is a very promising natural component for use in anti-allergic treatment.
  • [MeSH-minor] Animals. Basophil Degranulation Test. Basophils / drug effects. Basophils / metabolism. Chemical Fractionation. Chromatography, High Pressure Liquid. Ear Diseases / chemically induced. Ear Diseases / drug therapy. Edema / chemically induced. Edema / drug therapy. Humans. Leukocytes, Mononuclear / drug effects. Leukocytes, Mononuclear / metabolism. Leukotrienes / biosynthesis. Mice. Rats

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18703753.001).
  • [ISSN] 1535-3702
  • [Journal-full-title] Experimental biology and medicine (Maywood, N.J.)
  • [ISO-abbreviation] Exp. Biol. Med. (Maywood)
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Allergic Agents; 0 / Anti-Inflammatory Agents; 0 / Leukotrienes; 0 / Plant Extracts
  •  go-up   go-down


Advertisement
4. Brcić L, Vuletić LB, Stepan J, Bonevski A, Jakovljević G, Gasparov S, Marjanović K, Seiwerth S: Mast-cell sarcoma of the tibia. J Clin Pathol; 2007 Apr;60(4):424-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The mast-cell sarcoma of a bone is described here for the first time.
  • The cytoplasm around them was eosinophilic with many basophilic and toluidine-blue-positive granules.
  • The primary disease quickly progressed to mast-cell leukaemia, and despite intensive chemotherapy the patient died 18 months after first symptoms.
  • [MeSH-minor] Child, Preschool. Disease Progression. Fatal Outcome. Humans. Male. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Leuk Res. 2001 Jul;25(7):603-25 [11377686.001]
  • [Cites] Am J Surg Pathol. 2003 Jul;27(7):1013-9 [12826896.001]
  • [Cites] J Clin Pathol. 1986 Jun;39(6):596-602 [3088063.001]
  • [Cites] Mod Pathol. 1999 Jul;12(7):739-43 [10430280.001]
  • [CommentIn] J Clin Pathol. 2011 Nov;64(11):1035-7 [21778298.001]
  • (PMID = 17405977.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2001118
  •  go-up   go-down


5. Masamoto Y, Nannya Y, Arai S, Koike Y, Hangaishi A, Yatomi Y, Kurokawa M: Evidence for basophilic differentiation of acute promyelocytic leukaemia cells during arsenic trioxide therapy. Br J Haematol; 2009 Mar;144(5):798-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evidence for basophilic differentiation of acute promyelocytic leukaemia cells during arsenic trioxide therapy.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Arsenicals / therapeutic use. Basophils / pathology. Leukemia, Promyelocytic, Acute / pathology. Oxides / therapeutic use
  • [MeSH-minor] Cell Differentiation / drug effects. Humans. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. ARSENIC TRIOXIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19036092.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Arsenicals; 0 / Oxides; S7V92P67HO / arsenic trioxide
  •  go-up   go-down


6. Lee JH, Kim JW, Ko NY, Mun SH, Kim DK, Kim JD, Kim HS, Lee KR, Kim YK, Radinger M, Her E, Choi WS: Camellia japonica suppresses immunoglobulin E-mediated allergic response by the inhibition of Syk kinase activation in mast cells. Clin Exp Allergy; 2008 May;38(5):794-804
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Novel approaches are being explored to develop new therapies for various allergic diseases.
  • Complementary and alternative medicines are considered to be promising avenues for the development of such new therapies.
  • LECJ reversibly inhibited degranulation in a dose-dependent manner, with IC(50) values of approximately 50 microg/mL for the mast cells, and it also suppressed the expression and secretion of TNF-alpha and IL-4 in rat basophilic leukaemia-2H3 mast cells.
  • CONCLUSION: The present results strongly suggest that the anti-allergic activity of LECJ is mediated through inhibiting degranulation and allergic cytokine secretion by inhibition of Src-family kinase in mast cells and it may be useful for the treatment of mast cell-related immediate and delayed allergic diseases.
  • [MeSH-major] Camellia / chemistry. Intracellular Signaling Peptides and Proteins / antagonists & inhibitors. Mast Cells / drug effects. Plant Extracts / pharmacology. Plant Leaves / chemistry. Protein-Tyrosine Kinases / antagonists & inhibitors
  • [MeSH-minor] Animals. Basophils. Cell Degranulation. Cells, Cultured. Enzyme Activation. Humans. Hypersensitivity, Delayed / drug therapy. Hypersensitivity, Immediate / drug therapy. Immunoblotting. Immunoglobulin E / immunology. Immunoprecipitation. Korea. Mice. Mice, Inbred BALB C. Mice, Inbred ICR. Passive Cutaneous Anaphylaxis. Rats. Reverse Transcriptase Polymerase Chain Reaction. src-Family Kinases / antagonists & inhibitors

  • PhosphoSitePlus. gene/protein/disease-specific - PhosphoSitePlus® - comprehensive post-translational modification resource .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Clin Exp Allergy. 2008 May;38(5):704-8 [18325033.001]
  • (PMID = 18261158.001).
  • [ISSN] 1365-2222
  • [Journal-full-title] Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology
  • [ISO-abbreviation] Clin. Exp. Allergy
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Intracellular Signaling Peptides and Proteins; 0 / Plant Extracts; 37341-29-0 / Immunoglobulin E; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Syk kinase; EC 2.7.10.2 / src-Family Kinases
  •  go-up   go-down


7. Maruo T, Namikawa K, Kunihiro A, Lynch J, Shida T, Kishikawa S: Large granular lymphocytic leukaemia complicated with histiocytic sarcoma in a dog. J S Afr Vet Assoc; 2009 Dec;80(4):261-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Large granular lymphocytic leukaemia complicated with histiocytic sarcoma in a dog.
  • Seventy-two per cent (81360/ml) of the lymphocytes were found to be 12-17 microm in diameter, containing nuclei with mature clumped chromatin and abundant lightly basophilic cytoplasm with a variable number of fine azurophilic granules.
  • Based on these findings this case was diagnosed as LGL leukaemia.
  • As a result of multiple-agent chemotherapy, the markedly elevated levels of lymphocytes gradually decreased to 7500/ml on day 122 and the patient maintained a good quality of life for the following 3 months.
  • Shortly after diagnosis, the dog developed sudden onset of central nervous system signs and died on day 270.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Histiocytic Sarcoma / veterinary. Leukemia, Large Granular Lymphocytic / veterinary
  • [MeSH-minor] Animals. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Dog Diseases. Dogs. Fatal Outcome. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20458870.001).
  • [ISSN] 1019-9128
  • [Journal-full-title] Journal of the South African Veterinary Association
  • [ISO-abbreviation] J S Afr Vet Assoc
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] South Africa
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


8. Blonski WC, Katzka DA, Lichtenstein GR, Metz DC: Idiopathic gastric acid hypersecretion presenting as a diarrheal disorder and mimicking both Zollinger-Ellison syndrome and Crohn's disease. Eur J Gastroenterol Hepatol; 2005 Apr;17(4):441-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Idiopathic gastric acid hypersecretion presenting as a diarrheal disorder and mimicking both Zollinger-Ellison syndrome and Crohn's disease.
  • Many gastric acid hypersecretory states (basal acid output of greater than 15.0 mEq/h) exist for which the etiology is known, such as Zollinger-Ellison syndrome, systemic mastocytosis, antral exclusion, antral predominant Helicobacter pylori gastritis (antral G cell hyperplasia), chronic gastric outlet obstruction, short gut syndrome and basophilic leukemias.
  • However, many hypersecretory patients have no identified etiology for their acid hypersecretion and are designated as idiopathic gastric acid hypersecretors with a basal acid output of greater than 10 mEq/h and a normal serum gastrin level.
  • Idiopathic gastric acid hypersecretion represents a known cause of gastric acid hypersecretion that is far more common than Zollinger-Ellison syndrome and it has a markedly different treatment regimen and natural history.
  • We report a case of a patient with idiopathic gastric acid hypersecretion previously misdiagnosed as having Crohn's disease because of a presenting complaint of diarrhea and mimicking Zollinger-Ellison syndrome because her fasting serum gastrin level was elevated when incorrectly measured in the presence of antisecretory treatment.
  • [MeSH-minor] Adult. Anti-Ulcer Agents / therapeutic use. Diagnosis, Differential. Diarrhea / blood. Diarrhea / diagnosis. Diarrhea / drug therapy. Female. Gastrins / blood. Humans. Omeprazole / therapeutic use

  • Genetic Alliance. consumer health - Crohn Disease.
  • Genetic Alliance. consumer health - Zollinger-Ellison syndrome.
  • MedlinePlus Health Information. consumer health - Crohn's Disease.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. OMEPRAZOLE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Eur J Gastroenterol Hepatol. 2005 Dec;17(12):1433 [16292103.001]
  • [CommentIn] Eur J Gastroenterol Hepatol. 2005 Sep;17(9):1001 [16093882.001]
  • (PMID = 15756097.001).
  • [ISSN] 0954-691X
  • [Journal-full-title] European journal of gastroenterology & hepatology
  • [ISO-abbreviation] Eur J Gastroenterol Hepatol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-Ulcer Agents; 0 / Gastrins; KG60484QX9 / Omeprazole
  • [Number-of-references] 28
  •  go-up   go-down


9. Zhou J, Liu DF, Liu C, Kang ZM, Shen XH, Chen YZ, Xu T, Jiang CL: Glucocorticoids inhibit degranulation of mast cells in allergic asthma via nongenomic mechanism. Allergy; 2008 Sep;63(9):1177-85
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Using whole-cell patch clamp and fluorometric assay, we examined GCs' nongenomic effect on IgE-mediated exocytosis and histamine release of rat basophilic leukaemia-2H3 mast cells.
  • CONCLUSIONS: The study suggested for the first time that nongenomic pathway was involved in GCs' rapid inhibition on allergic asthma, and raised the possibility of new therapeutic strategies for allergic diseases including asthma.
  • [MeSH-major] Anti-Inflammatory Agents / pharmacology. Cell Degranulation / drug effects. Glucocorticoids / pharmacology. Mast Cells / drug effects
  • [MeSH-minor] Animals. Asthma / drug therapy. Guinea Pigs. Histamine / metabolism. Male. Time Factors

  • MedlinePlus Health Information. consumer health - Steroids.
  • Hazardous Substances Data Bank. HISTAMINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18699934.001).
  • [ISSN] 1398-9995
  • [Journal-full-title] Allergy
  • [ISO-abbreviation] Allergy
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents; 0 / Glucocorticoids; 820484N8I3 / Histamine
  •  go-up   go-down






Advertisement